Menstrual Cycle and Platelet-rich Fibrin

Necmettin Erbakan University

Status: Not yet enrolling

Conditions: Menstrual Cycle

Treatments: Device: Platelet rich fibrin device

Study type: Observational

Funder types: Other

Identifiers

NCT06060574

PRFzeynep

Details and patient eligibility

About

The goal of this clinical trial is to test effect of menstrual cycle (MC) on growth factors of platelet rich fibrin (PRF) in health condition. The main questions it aims to answer are:

question 1: Does MC have an effect on growth factors in PRF? question 2: In which menstrual phase are growth factors higher? question 3:Does the change in the number of blood cells in the menstrual cycle have an effect on PRF? Participants will describe the main tasks participants will be asked to do.

Full description

Abstract Platelet-rich fibrin (PRF) is frequently used in periodontal regenerative treatments. Thanks to the growth factors in its content, it affects the healing positively. Studies have shown that the size and content of PRF are affected by variables such as age, gender, centrifugation speed and inflammation.

It is known that during the menstrual cycle (MS) phases in women, changes occur in cell numbers and growth factors in the blood. The aim of this study is to determine the size of the PRF and the epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), platelet-derived growth factor-BB (PDGF-BB), transforming growth factor-β1 (TGF-β1) and vascular endothelial growth factor (VEGF).

PRF membrane will be formed from the blood of each individual in the study, taken on days 1-2 (M), 8-10 (PF), 12-14 (OD) and days 22-24 before menstruation (PmD). The size of the membranes will be measured. On the same days, individuals will have a complete blood count. The growth factors levels of each PRF membrane obtained at the 1st, 24th and 72nd hours will be determined.

At the end of the study, the growth factors contents of the PRF membranes obtained in different phases of MS will be compared. In addition, the effect of the results of the complete blood count of the individuals on the PRF membrane will be evaluated.

Enrollment: 36 estimated patients

Sex: Female

Ages: 20 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Having a regular MS in the last three periods and a menstrual period lasting 5-7 days,
• Not using contraceptive drugs and/or drugs that affect sex hormones,
• With less than 10% bleeding on probing within 10 seconds after probing, that is, gingival ally healthy,
• Have not received any periodontal or orthodontic treatment until at least 6 months before the start of the study,
• Have not used antibiotics in the last 6 months for any reason
• Systemically healthy individuals without prosthetic restoration in their mouths will be included.

Exclusion criteria

• Those who have any systemic disease and drug use related to it
• Pregnant or breastfeeding
• have recently used aspirin or have a disease related to the clotting process
• Refusing to participate in the study

Trial design

36 participants in 4 patient groups

Menstrual Cycle 1-2nd days

Description:

The Blood samples will be drawn from the participants on 1st-2nd day of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.

Treatment:

Device: Platelet rich fibrin device

Menstrual Cycle 8-10. days : proliferative phase (PP)

Description:

The Blood samples will be drawn from the participants on 8-10. days of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.

Treatment:

Device: Platelet rich fibrin device

Menstrual Cycle 12-14. days: ovulation phase (OP)

Description:

The Blood samples will be drawn from the participants on 12-14. days of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.

Treatment:

Device: Platelet rich fibrin device

premenstrual (PmD) 22-24. days

Description:

The Blood samples will be drawn from the participants on 22-24. days of the menstrual cycle of each of these 36 participants. PRF will be obtained from the blood taken these days.

Treatment:

Device: Platelet rich fibrin device